Article
Oncology
Jiannong Li, Inna Smalley, Zhihua Chen, Jheng-Yu Wu, Manali S. Phadke, Jamie K. Teer, Thanh Nguyen, Florian A. Karreth, John M. Koomen, Amod A. Sarnaik, Jonathan S. Zager, Nikhil I. Khushalani, Ahmad A. Tarhini, Vernon K. Sondak, Paulo C. Rodriguez, Jane L. Messina, Y. Ann Chen, Keiran S. M. Smalley
Summary: This study used single-cell RNA sequencing to analyze acral melanoma and found that it has a suppressed immune environment compared to non-acral cutaneous melanoma. Multiple therapeutically tractable immune checkpoints were observed in acral melanoma, offering new options for clinical translation.
CLINICAL CANCER RESEARCH
(2022)
Article
Biochemistry & Molecular Biology
Ahlem Jebali, Maxime Battistella, Celeste Lebbe, Nicolas Dumaz
Summary: The network involving PI3K, AKT, and mTOR is important in melanoma oncogenesis, with RICTOR overexpression associated with poor prognosis. RICTOR enhances melanoma-initiating cells with stemness properties and contributes to resistance to BRAF inhibitors. An interaction between RICTOR and STAT3 in resistant cells, as well as a connection between RAS and RICTOR in resistant melanoma, were identified, suggesting RICTOR as a valuable therapeutic target in melanoma.
Article
Oncology
Manali S. Phadke, Zhihua Chen, Jiannong Li, Eslam Mohamed, Michael A. Davies, Inna Smalley, Derek R. Duckett, Vinayak Palve, Brian J. Czerniecki, Peter A. Forsyth, David Noyes, Dennis O. Adeegbe, Zeynep Eroglu, Kimberly T. Nguyen, Kenneth Y. Tsai, Uwe Rix, Christin E. Burd, Yian A. Chen, Paulo C. Rodriguez, Keiran S. M. Smalley
Summary: In mouse models of BRAF- and NRAS-mutant melanoma, upfront immunotherapy enhances responses to targeted therapy. The sequence of IT -> TT modulates the immune environment, increasing infiltration of T cells and decreasing tumor-associated macrophages, leading to improved therapeutic outcomes. Durable responses to the IT -> TT sequence depend on T-cell activity and enrichment of a population of melanoma cells with increased expression of MHC class I and melanoma antigens.
CANCER IMMUNOLOGY RESEARCH
(2021)
Review
Oncology
Manuel Felipe Fernandez, Jacob Choi, Jeffrey Sosman
Summary: Immune checkpoint inhibitors and BRAF/MEK inhibitors are the main treatments for melanoma, but resistance to these therapies emphasizes the need for new treatment options. Monoclonal antibodies and small molecules allow targeted therapy by focusing on specific mediators of cancer. Melanoma has several driver mutations, and targeting them could lead to novel therapies.
Editorial Material
Oncology
Meghan J. J. Mooradian, Ryan J. J. Sullivan
Summary: The development of effective BRAF-targeted therapy and immune checkpoint inhibition has revolutionized the treatment of advanced metastatic melanoma. However, it remains unclear which treatment option is the best for patients with resected, BRAF-mutant stage III melanoma. This article presents arguments for and against the use of BRAF-targeted therapy and immunotherapy in these patients.
Article
Oncology
Pawel Rogala, Anna M. Czarnecka, Bozena Cybulska-Stopa, Krzysztof Ostaszewski, Karolina Piejko, Marcin Zietek, Robert Dziura, Ewa Rutkowska, Lukasz Galus, Natasza Kempa-Kaminska, Joanna Seredynska, Wieslaw Bal, Katarzyna Kozak, Anna Surus-Hyla, Tomasz Kubiatowski, Grazyna Kaminska-Winciorek, Rafal Suwinski, Jacek Mackiewicz, Piotr Rutkowski
Summary: This study aimed to evaluate the association between different genotypes of human papillomavirus (HPV) and the risk of cervical cancer in Sichuan province, China.
Article
Multidisciplinary Sciences
Anastasia Samarkina, Markus Kirolos Youssef, Paola Ostano, Soumitra Ghosh, Min Ma, Beatrice Tassone, Tatiana Proust, Giovanna Chiorino, Mitchell P. Levesque, Sandro Goruppi, Gian Paolo Dotto
Summary: Androgen receptor expression is linked to BRAF inhibitor response and targeting AR could be a potential co-therapeutic approach to increase efficacy in melanoma treatment.
NATURE COMMUNICATIONS
(2023)
Article
Oncology
Max J. Karlsson, Fernanda Costa Svedman, Abdellah Tebani, David Kotol, Veronica Hoiom, Linn Fagerberg, Fredrik Edfors, Mathias Uhlen, Suzanne Egyhazi Brage, Gianluca Maddalo
Summary: A study on malignant cutaneous melanoma identified potential biomarkers that could predict patient response to therapy, paving the way for personalized treatment strategies in the future.
Article
Biochemistry & Molecular Biology
Elena Lastraioli, Federico Alessandro Ruffinatti, Giacomo Bagni, Luca Visentin, Francesco di Costanzo, Luca Munaron, Annarosa Arcangeli
Summary: In melanoma, immune response and proteasome are associated with tumor development, while genes related to cytosolic ribosomes show a downregulated trend, and transcripts coding for mitoribosome proteins show the opposite trend.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Oncology
Shahla Bari, Jameel Muzaffar, Zeynep Eroglu
Summary: Activating BRAFV600 mutation accounts for 50% of advanced melanomas. Targeted therapy with BRAF inhibitors has shown impressive responses but resistance remains a challenge. Immunotherapy using immune checkpoint blockers has exhibited durable disease control in BRAF-mutated melanoma patients. Combining targeted therapy with immune therapy may be a promising approach for long-term disease control.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Alexandra Landras, Coralie Reger de Moura, Bruno O. Villoutreix, Maxime Battistella, Aurelie Sadoux, Nicolas Dumaz, Suzanne Menashi, Juan Fernandez-Recio, Celeste Lebbe, Samia Mourah
Summary: CD147i, a specific inhibitor of CD147/VEGFR-2 interaction, shows potential therapeutic effects for NRAS(mut) melanoma cells. It significantly inhibits malignant properties of melanoma and exhibits synergy with MEKi.
Review
Oncology
Maximilian Haist, Henner Stege, Michael Kuske, Julia Bauer, Annika Klumpp, Stephan Grabbe, Matthias Bros
Summary: The approval of immune-checkpoint inhibitors (CPI) and mitogen activated protein kinase inhibitors (MAPKi) has greatly improved the treatment and survival of patients with advanced malignant melanoma. Preclinical data suggests that the combined application of CPI and MAPKi can provide additional clinical benefit. Clinical trials investigating the sequential or combined use of these inhibitors are discussed, along with their implications for clinical practice and the limitations of current treatments.
CANCER AND METASTASIS REVIEWS
(2023)
Article
Oncology
Kiran Kumar Reddi, Praveen Guruvaiah, Yvonne J. K. Edwards, Romi Gupta
Summary: The study identified new targets and mechanisms driving resistance to MAPK pathway inhibitors in melanoma cells through unbiased RNA-sequencing and ATAC-seq. Changes in chromatin accessibility affected the expression levels of multiple genes, modulating oncogenic pathways and promoting resistance to inhibitors. This research provides potential new targets for treating melanoma patients resistant to MEK or BRAF inhibitors.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Nakul Dar, Sarah E. Gradecki, Elizabeth M. Gaughan
Summary: Targeted therapies, such as BRAF and MEK inhibitors, are important treatment options for patients with advanced melanoma. Sarcoidosis, a non-caseating granulomatous inflammation, is associated with melanoma and is increasingly seen in patients undergoing anti-melanoma therapy. Differentiating sarcoidosis from malignancy-related findings is a challenge for clinicians.
FRONTIERS IN ONCOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Lisa Elefanti, Carolina Zamuner, Paolo Del Fiore, Camilla Stagni, Stefania Pellegrini, Luigi Dall'Olmo, Alessio Fabozzi, Rebecca Senetta, Simone Ribero, Roberto Salmaso, Simone Mocellin, Franco Bassetto, Francesco Cavallin, Anna Lisa Tosi, Francesca Galuppini, Angelo Paolo Dei Tos, Chiara Menin, Rocco Cappellesso
Summary: Acral melanoma is a rare and aggressive subtype of melanoma, unrelated to UV radiation, with low mutation burden but frequent chromosomal rearrangements and gene amplifications. The most commonly mutated genes are BRAF, NRAS, and TP53, with some genetic alterations associated with histologic prognostic features.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Multidisciplinary Sciences
V. Gopalakrishnan, C. N. Spencer, L. Nezi, A. Reuben, M. C. Andrews, T. V. Karpinets, P. A. Prieto, D. Vicente, K. Hoffman, S. C. Wei, A. P. Cogdill, L. Zhao, C. W. Hudgens, D. S. Hutchinson, T. Manzo, M. Petaccia de Macedo, T. Cotechini, T. Kumar, W. S. Chen, S. M. Reddy, R. Szczepaniak Sloane, J. Galloway-Pena, H. Jiang, P. L. Chen, E. J. Shpall, K. Rezvani, A. M. Alousi, R. F. Chemaly, S. Shelburne, L. M. Vence, P. C. Okhuysen, V. B. Jensen, A. G. Swennes, F. McAllister, E. Marcelo Riquelme Sanchez, Y. Zhang, E. Le Chatelier, L. Zitvogel, N. Pons, J. L. Austin-Breneman, L. E. Haydu, E. M. Burton, J. M. Gardner, E. Sirmans, J. Hu, A. J. Lazar, T. Tsujikawa, A. Diab, H. Tawbi, I. C. Glitza, W. J. Hwu, S. P. Patel, S. E. Woodman, R. N. Amaria, M. A. Davies, J. E. Gershenwald, P. Hwu, J. E. Lee, J. Zhang, L. M. Coussens, Z. A. Cooper, P. A. Futreal, C. R. Daniel, N. J. Ajami, J. F. Petrosino, M. T. Tetzlaff, P. Sharma, J. P. Allison, R. R. Jenq, J. A. Wargo
Article
Oncology
Rodabe N. Amaria, Peter A. Prieto, Michael T. Tetzlaff, Alexandre Reuben, Miles C. Andrews, Merrick J. Ross, Isabella C. Glitza, Janice Cormier, Wen-Jen Hwu, Hussein A. Tawbi, Sapna P. Patel, Jeffrey E. Lee, Jeffrey E. Gersbenwaid, Christine N. Spencer, Vancheswaran Gopalakrishnan, Roland Bassett, Lauren Simpson, Rosalind Mouton, Courtney W. Hudgens, Li Zhao, Haifeng Zhu, Zachary A. Cooper, Khalida Wani, Alexander Lazar, Patrick Hwu, Adi Diab, Michael K. Wong, Jennifer L. McQuade, Richard Royal, Anthony Lucci, Elizabeth M. Burton, Sangeetha Reddy, Padmanee Sharma, James Allison, Phillip A. Futreal, Scott E. Woodman, Michael A. Davies, Jennifer A. Wargo
Article
Oncology
Meghan J. Mooradian, Alexandre Reuben, Peter A. Prieto, Mehlika Hazar-Rethinam, Dennie T. Frederick, Brandon Nadres, Adriano Piris, Vikram Juneja, Zachary A. Cooper, Arlene H. Sharpe, Ryan B. Corcoran, Keith T. Flaherty, Donald P. Lawrence, Jennifer A. Wargo, Ryan J. Sullivan
Article
Oncology
Shelly Kalaora, Yochai Wolf, Tali Feferman, Eilon Barnea, Erez Greenstein, Dan Reshef, Itay Tirosh, Alexandre Reuben, Sushant Patkar, Ronen Levy, Juliane Quinkhardt, Tana Omokoko, Nouar Qutob, Ofra Golani, Jianhua Zhang, Xizeng Mao, Xingzhi Song, Chantale Bernatchez, Cara Haymaker, Marie-Andree Forget, Caitlin Creasy, Polina Greenberg, Brett W. Carter, Zachary A. Cooper, Steven A. Rosenberg, Michal Lotem, Ugur Sahin, Guy Shakhar, Eytan Ruppin, Jennifer A. Wargo, Nir Friedman, Arie Admon, Yardena Samuels
Correction
Biochemistry & Molecular Biology
Moshe Sade-Feldman, Keren Yizhak, Stacey L. Bjorgaard, John P. Ray, Carl G. de Boer, Russell W. Jenkins, David J. Lieb, Jonathan H. Chen, Dennie T. Frederick, Michal Barzily-Rokni, Samuel S. Freeman, Alexandre Reuben, Paul J. Hoover, Alexandra-Chloe Villani, Elena Ivanova, Andrew Portell, Patrick H. Lizotte, Amir R. Aref, Jean-Pierre Eliane, Marc R. Hammond, Hans Vitzthum, Shauna M. Blackmon, Bo Li, Vancheswaran Gopalakrishnan, Sangeetha M. Reddy, Zachary A. Cooper, Cloud P. Paweletz, David A. Barbie, Anat Stemmer-Rachamimov, Keith T. Flaherty, Jennifer A. Wargo, Genevieve M. Boland, Ryan J. Sullivan, Gad Getz, Nir Hacohen
Article
Biochemistry & Molecular Biology
Moshe Sade-Feldman, Keren Yizhak, Stacey L. Bjorgaard, John P. Ray, Carl G. de Boer, Russell W. Jenkins, David J. Lieb, Jonathan H. Chen, Dennie T. Frederick, Michal Barzily-Rokni, Samuel S. Freeman, Alexandre Reuben, Paul J. Hoover, Alexandra-Chloe Villani, Elena Ivanova, Andrew Portell, Patrick H. Lizotte, Amir R. Aref, Jean-Pierre Eliane, Marc R. Hammond, Hans Vitzthum, Shauna M. Blackmon, Bo Li, Vancheswaran Gopalakrishnan, Sangeetha M. Reddy, Zachary A. Cooper, Cloud P. Paweletz, David A. Barbie, Anat Stemmer-Rachamimov, Keith T. Flaherty, Jennifer A. Wargo, Genevieve M. Boland, Ryan J. Sullivan, Gad Getz, Nir Hacohen
Article
Biochemical Research Methods
Arnaud Amzallag, Sridhar Ramaswamy, Cyril H. Benes
BMC BIOINFORMATICS
(2019)
Article
Pathology
Krishnan K. Mahadevan, Kshitij S. Arora, Arnaud Amzallag, Erik Williams, Anupriya S. Kulkarni, Carlos Fernandez-del Castillo, Keith D. Lillemoe, Nabeel Bardeesy, Theodore S. Hong, Cristina R. Ferrone, David T. Ting, Vikram Deshpande
Article
Biochemistry & Molecular Biology
Avinash Das Sahu, Joo S. Lee, Zhiyong Wang, Gao Zhang, Ramiro Iglesias-Bartolome, Tian Tian, Zhi We, Benchun Miao, Nishanth Ulhas Nair, Olga Ponomarova, Adam A. Friedman, Arnaud Amzallag, Tabea Moll, Gyulnara Kasumova, Patricia Greninger, Regina K. Egan, Leah J. Damon, Dennie T. Frederick, Livnat Jerby-Arnon, Allon Wagner, Kuoyuan Cheng, Seung Gu Park, Welles Robinson, Kevin Gardner, Genevieve Boland, Sridhar Hannenhalli, Meenhard Herlyn, Cyril Benes, Keith Flaherty, Ji Luo, J. Silvio Gutkind, Eytan Ruppin
MOLECULAR SYSTEMS BIOLOGY
(2019)
Article
Oncology
Ashvin R. Jaiswal, Arthur J. Liu, Shivanand Pudakalakatti, Prasanta Dutta, Priyamvada Jayaprakash, Todd Bartkowiak, Casey R. Ager, Zhi-Qiang Wang, Alexandre Reuben, Zachary A. Cooper, Cristina Ivan, Zhenlin Ju, Felix Nwajei, Jing Wang, Michael A. Davies, R. Eric Davis, Jennifer A. Wargo, Pratip K. Bhattacharya, David S. Hong, Michael A. Curran
CANCER IMMUNOLOGY RESEARCH
(2020)
Article
Oncology
Lillian Siu, Joshua Brody, Shilpa Gupta, Aurelien Marabelle, Antonio Jimeno, Pamela Munster, Juneko Grilley-Olson, Alain H. Rook, Antoine Hollebecque, Rebecca K. S. Wong, James W. Welsh, Yuling Wu, Christopher Morehouse, Oday Hamid, Farzana Walcott, Zachary A. Cooper, Rakesh Kumar, Charles Ferte, David S. Hong
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2020)
Review
Oncology
Fred R. Hirsch, Jill Walker, Brandon W. Higgs, Zachary A. Cooper, Rajiv G. Raja, Ignacio I. Wistuba
Summary: Diagnosing cancer is often inefficient and delays treatment. The combiome approach proposes a more efficient and comprehensive diagnosis by combining information from the tumor and patient's immune system. Faster and optimized diagnostic testing is needed for complex treatment decisions. Adopting the combiome model can lead to better outcomes for cancer patients, but requires significant changes.
CLINICAL LUNG CANCER
(2022)
Article
Veterinary Sciences
Leeza Birdwell, Denyse Levesque, Deepa Machiah, Sanjeev Gumber
Summary: This study examined the differences in pancreatic islet amyloid deposition between diabetic and non-diabetic monkeys using histopathology and immunohistochemistry. The results showed that diabetic monkeys had more severe amyloid deposition in the pancreas compared to non-diabetic monkeys. Furthermore, there were differences in pancreatic hormones and islet amyloid components between the two species and their diabetic status.
JOURNAL OF MEDICAL PRIMATOLOGY
(2022)
Article
Oncology
Krista Kinneer, Philipp Wortmann, Zachary A. Cooper, Niall J. Dickinson, Luke Masterson, Thais Cailleau, Ian Hutchinson, Balakumar Vijayakrishnan, Mary McFarlane, Kathryn Ball, Michael Davies, Arthur Lewis, Yue Huang, Anton I. Rosenbaum, Jiaqi Yuan, Jon Chesebrough, Judith Anderton, Noel Monks, Steven Novick, Jixin Wang, Nazzareno Dimasi, R. James Christie, Darrin Sabol, Frances Anne Tosto, Yann Wallez, Elisabetta Leo, Mark R. Albertella, Anna D. Staniszewska, David A. Tice, Philip W. Howard, Nadia Luheshi, Puja Sapra
Summary: This study evaluated the activity of AZD8205, a B7-H4-directed ADC bearing a novel TOP1i payload, alone and in combination with AZD5305, in preclinical models. The results showed the potential therapeutic effect of AZD8205 on B7-H4-expressing tumors and supported an ongoing phase 1 clinical study.
CLINICAL CANCER RESEARCH
(2023)
Article
Oncology
Luana Guimaraes Sousa, Daniel J. McGrail, Felippe Lazar Neto, Kaiyi Li, Mario L. Marques-Piubelli, Sammy Ferri-Borgogno, Hui Dai, Yoshitsugu Mitani, Nicole Spardy Burr, Zachary A. Cooper, Krista Kinneer, Maria Angelica Cortez, Shiaw-Yih Lin, Diana Bell, Adel El Naggar, Jared Burks, Renata Ferrarotto
Summary: This study explored the tumor microenvironment (TME) of adenoid cystic carcinoma (ACC) and found that different ACC subtypes have distinct TMEs. The ACC-I subtype showed higher immune cell density, but these cells were primarily located in the stroma, characterizing an immune-excluded TME. The high expression of the immune checkpoint B7-H4 in ACC-I was directly correlated with the degree of immune exclusion and poor prognosis.
CLINICAL CANCER RESEARCH
(2023)